Peli BioThermal Expands Cold Chain Solutions Through Strategic Acquisition
Peli BioThermal's Strategic Acquisition to Enhance Offerings
Acquisition strengthens portfolio, accelerates innovation and expands reach to new markets.
Peli BioThermal, a leader in temperature-controlled logistics solutions, has successfully completed the acquisition of Evo from BioLife Solutions. This strategic move is set to enhance Peli BioThermal's already impressive portfolio of products and services specifically tailored for the pharmaceutical value chain. The Evo portfolio, which includes advanced cryogenic shippers and the evoIS technology platform, is designed to meet the pressing demands of the quickly expanding Cell and Gene Therapy sector.
By integrating Evo's offerings, Peli BioThermal strengthens its capacity to deliver an extensive variety of cold chain solutions, allowing it to cater effectively to existing customers while also opening doors to engage with new clients in the pharmaceutical, biopharmaceutical, and clinical supply arenas. This initiative aims to provide current Evo users with greater convenience by sourcing solutions directly through Peli BioThermal while enhancing the product line through accelerated development and innovation.
The addition of Evo products holds significant importance for the Cell and Gene Therapy market, where cryogenic transport, precision, reliability, and flexibility are vital for successfully delivering life-saving therapies to patients. The need for effective cold chain logistics has never been more critical, and with this acquisition, Peli BioThermal is set to lead the charge in meeting those challenges.
Sam Herbert, the CEO of Peli BioThermal, expressed enthusiasm over the acquisition, stating, "The addition of Evo is a strategic step forward that rounds out our solutions portfolio and reinforces our commitment to solving our customers' toughest cold chain challenges. Peli BioThermal customers will enjoy greater choice and convenience, while Evo customers will gain access to our global expertise and support network as their needs evolve. The legacy provided by BioLife Solutions and SAVSU has been noteworthy, and as we embark on this new journey, we will dedicate our capabilities to expanding and innovating at an accelerated pace."
The integration of Evo's offerings aligns well with Peli BioThermal's flagship solutions like the Cr?do reusable shippers and NanoCool systems, along with the newly introduced Cr?do Vault bulk shipper and V?ro One single-use dry ice shipper. This comprehensive integration allows customers to optimize their choices according to sustainability, performance demands, or operational ease, significantly increasing their decision-making flexibility.
This transaction marks Peli BioThermal and Pelican Products' second additional acquisition since being acquired by Platinum Equity. This consistent momentum in growth indicates strong confidence in Peli BioThermal's future.
According to statements from Platinum Equity Co-President Jacob Kotzubei and Managing Director Matthew Louie, "Evo will allow Peli BioThermal to offer a complete range of temperature-controlled solutions. This capability will deepen relationships with existing customers while providing access to high-growth end markets. Our commitment to investing in Peli BioThermal is generating significant momentum, and we are thrilled about the direction in which the company is headed."
The operations and team based in Bruce Township, MI, which are associated with Evo, will remain intact as part of Peli BioThermal. This continuity will ensure that customers receive expert support while leveraging Peli BioThermal's extensive global resources to facilitate growth.
About Peli BioThermal
Peli BioThermal is recognized globally as a leader in temperature-controlled logistics solutions, providing a complete array of single-use and reusable products and services aimed at the life sciences industry. With decades of expertise in reliability and quality, Peli BioThermal's solutions are critical for safeguarding life-saving medicines throughout the global cold chain, ensuring their effectiveness and safety during transport.
Frequently Asked Questions
What strategic move did Peli BioThermal recently make?
Peli BioThermal acquired Evo from BioLife Solutions to enhance its portfolio in cold chain logistics.
What is the significance of the Evo product line?
The Evo product line provides advanced cryogenic shippers optimized for the Cell and Gene Therapy market.
How does this acquisition benefit Peli BioThermal's customers?
The acquisition enhances choice and convenience, offering a broader range of solutions for existing and new customers.
What are some of Peli BioThermal's product offerings?
Peli BioThermal’s solutions include Cr?do reusable shippers, NanoCool systems, and Cr?do Vault bulk shippers.
How does Peli BioThermal's acquisition strategy reflect its market position?
This acquisition strategy reflects Peli BioThermal's commitment to innovation and expansion in the rapidly evolving cold chain logistics sector.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
